Nuveen Asset Management LLC Sells 57,329 Shares of The Chemours Company (NYSE:CC)

Nuveen Asset Management LLC reduced its position in The Chemours Company (NYSE:CC - Free Report) by 19.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 243,437 shares of the specialty chemicals company's stock after selling 57,329 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.16% of Chemours worth $4,114,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Strategic Financial Concepts LLC acquired a new position in Chemours in the fourth quarter valued at approximately $357,000. Entropy Technologies LP acquired a new position in Chemours in the fourth quarter valued at approximately $266,000. Sei Investments Co. boosted its stake in Chemours by 779.5% in the fourth quarter. Sei Investments Co. now owns 174,555 shares of the specialty chemicals company's stock valued at $2,950,000 after acquiring an additional 154,709 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Chemours in the fourth quarter valued at approximately $515,000. Finally, Victory Capital Management Inc. boosted its stake in Chemours by 6.8% in the fourth quarter. Victory Capital Management Inc. now owns 110,311 shares of the specialty chemicals company's stock valued at $1,864,000 after acquiring an additional 7,052 shares during the period. 76.26% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CC has been the subject of a number of research reports. Wall Street Zen downgraded Chemours from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. Royal Bank of Canada reduced their price objective on Chemours from $17.00 to $14.00 and set an "outperform" rating for the company in a research report on Thursday, May 8th. Truist Financial reduced their price objective on Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Morgan Stanley reduced their price objective on Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a research report on Monday, May 12th. Finally, Mizuho set a $15.00 price objective on Chemours in a research report on Tuesday, April 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $17.22.

Insider Buying and Selling at Chemours

In related news, CFO Shane Hostetter purchased 4,450 shares of the stock in a transaction dated Monday, May 19th. The shares were acquired at an average cost of $11.28 per share, for a total transaction of $50,196.00. Following the acquisition, the chief financial officer now directly owns 59,694 shares in the company, valued at approximately $673,348.32. The trade was a 8.06% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Damian Gumpel purchased 7,822 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were bought at an average price of $9.95 per share, for a total transaction of $77,828.90. Following the completion of the acquisition, the insider now owns 131,701 shares in the company, valued at $1,310,424.95. This represents a 6.31% increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.47% of the stock is owned by corporate insiders.

Chemours Price Performance

NYSE:CC traded up $0.12 during midday trading on Wednesday, hitting $10.05. 3,041,422 shares of the stock were exchanged, compared to its average volume of 2,180,616. The Chemours Company has a one year low of $9.13 and a one year high of $25.80. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of 17.63 and a beta of 1.76. The business has a 50-day moving average price of $11.30 and a two-hundred day moving average price of $15.49. The company has a current ratio of 1.68, a quick ratio of 0.92 and a debt-to-equity ratio of 6.70.

Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.06). The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.36 billion. Chemours had a return on equity of 26.54% and a net margin of 1.51%. Chemours's revenue for the quarter was up .4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.32 EPS. Sell-side analysts predict that The Chemours Company will post 2.03 EPS for the current year.

Chemours Dividend Announcement

The business also recently declared a dividend, which will be paid on Monday, June 16th. Shareholders of record on Monday, May 19th will be issued a $0.0875 dividend. The ex-dividend date is Friday, May 16th. This represents a dividend yield of 3.17%. Chemours's dividend payout ratio is currently 175.00%.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.